Project Grant F32CA295075
Award Date 12/23/25
Completion Date 9/14/27
Dollars Obligated $151K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The U.S. National Cancer Institute awarded a $855,249 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports DFCI's research to develop new approaches for targeting cell cycle proteins as potential cancer treatments. The key focus is on investigating how abnormal activation of cyclin-dependent kinases (CDKs) drives uncontrolled tumor cell proliferation, and exploring strategies to overcome limitations of...
- The federal Project Grant award in the amount of $159,304 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398). The award was granted to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on signaling pathways in tumoricidal macrophages in pancreatic cancer. The key objectives of the project include defining the role of deubiquitinases in regulating macrophage surface receptors that govern the recognition and phagocytosis...
- The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $445,000 project grant to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant, awarded on January 22, 2025, supports DFCI's research on the molecular mechanisms of DNA double-strand break repair by homologous recombination, a critical process for cell survival and cancer prevention. The project aims to define the complex...
- This $160,500 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of mouse models to investigate the role of Caspase-2 in nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML). The project aims to determine the impact of Caspase-2 loss on the self-renewal and myeloproliferative disease progression of NPM1-mutated AML cells. The research is being conducted by the Baylor College of Medicine, a leading private,...
- This federal Project Grant award of $846,982 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports a research project titled "Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy" at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The research aims to advance the understanding of how the PD-1:SHP-2 axis in hematopoietic stem and progenitor cells impacts the differentiation and function of...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- This Project Grant award of $222,432 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to St. Jude Children's Research Hospital Inc. will fund research to investigate the role of the protein Caspase-8 in cancer, anti-cancer immunity, and CAR-T cell function. The two main aims of the project are: To understand the roles of Caspase-8 in cancer cells and its influence on anti-cancer immunity, including effects on proliferation, inflammatory signaling, resistance to CAR-T...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- This Project Grant award, titled "Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining its Regulation and Cellular Interactions", is funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) for $241,884.00. The award will be carried out by the Dana-Farber Cancer Institute, Inc. (DFCI) from September 3, 2025 through August 31, 2030. The project aims to characterize the role of the non-classical HLA-E molecule in immune evasion by diffuse large...